TY - JOUR T1 - A rapid, cost efficient and simple method to identify current SARS-CoV-2 variants of concern by Sanger sequencing part of the spike protein gene JF - medRxiv DO - 10.1101/2021.03.27.21252266 SP - 2021.03.27.21252266 AU - Tue Sparholt Jørgensen AU - Kai Blin AU - Franziska Kuntke AU - Henrik K. Salling AU - Thomas Y Michaelsen AU - Mads Albertsen AU - Helene Larsen Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/29/2021.03.27.21252266.abstract N2 - In 2020, the novel coronavirus, SARS-CoV-2, caused a pandemic, which is still raging at the time of writing this. Many countries have set up high throughput RT-qPCR based diagnostics for people with COVID-19 symptoms and for the wider population. In addition, with the use of whole genome sequencing (WGS) new lineages of SARS-CoV-2 have been identified that have been associated with increased transmissibility or altered vaccine efficacy, so-called Variants of Concern (VoC). WGS is generally too labor intensive and expensive to be applied to all positive samples from the diagnostic tests, and often has a turnaround time too long to enable VoC focused contact tracing. Here, we propose to use Sanger sequencing for the detection of common variants of concern and key mutations in early 2021, using a single set of the recognized ARTIC Network primers. The proposed setup relies entirely on materials and methods already in use in diagnostic RT-qPCR labs and on existing infrastructure from companies that have specialized in cheap and rapid turnaround Sanger sequencing. In addition, we provide an automated mutation calling software (https://github.com/kblin/covid-spike-classification). We have validated the setup on 195 SARS-CoV-2 positive samples, and we were able to profile >85% of RT-qPCR positive samples, where the last 15% largely stem from samples with low viral count. At approximately 4€ per sample in material cost, with minimal hands-on time, little data handling, and a turnaround time of less than 30 hours, the setup is simple enough to be implemented in any SARS-CoV-2 RT-qPCR diagnostic lab. Our protocol provides results that can be used to focus contact-tracing efforts and it is cheap enough for the tracking and surveillance of all positive samples for emerging variants such as B.1.1.7, B.1.351 and P.1 as of January 2021.Competing Interest StatementThe authors have declared no competing interest.Funding StatementT.S.J. and K.B. received support by The Novo Nordisk Foundation through the grants NNF-IIMENA (NNF16OC0021746) and NNF CFB (NNF20CC0035580). This work was supported by the Poul Due Jensen Fonden (Grundfos Fonden, Corona-Danica).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A waiver of ethical approval was received from the regional Copenhagen ethics committee. The decision to waive ethics approval was made by Cand.jur Jakob Hjelvang Lemming, jakob.lemming@regionh.dk, Region Hovedstaden, Center for Regional Udvikling, Sundhedsforskning og Innovation, De Videnskabsetiske Komiteer for Region Hovedstaden, Kongens Vaenge 2, 3400 Hilleroed, Denmark All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data will be made public after peer review. ER -